Lupin Launches Emtricitabine and Tenofovir Disoproxil Fumarate Tablets in the United States

Global pharma major Lupin Limited (Lupin) today announced the launch of Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg, having received an approval from the United States Food and Drug Administration (FDA).

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200 mg/300 mg, are the generic equivalent of Truvada® Tablets 200 mg/300 mg, of Gilead Sciences, Inc., and indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. It is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets (RLD: Truvada®) had estimated annual sales of USD 2.1 billion in the U.S. (IQVIA MAT March 2021).

Shares of LUPIN LTD. was last trading in BSE at Rs.1152.35 as compared to the previous close of Rs. 1139.45. The total number of shares traded during the day was 38852 in over 1929 trades.

The stock hit an intraday high of Rs. 1160.65 and intraday low of 1140.85. The net turnover during the day was Rs. 44735023.

Source : Equity Bulls

Keywords